表紙
市場調査レポート

再発性の急性骨髄性白血病:世界の治験レビュー

Relapsed Acute Myeloid Leukemia Global Clinical Trials Review, H1, 2014

発行 GlobalData 商品コード 300505
出版日 ページ情報 英文 119 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.51円で換算しております。
Back to Top
再発性の急性骨髄性白血病:世界の治験レビュー Relapsed Acute Myeloid Leukemia Global Clinical Trials Review, H1, 2014
出版日: 2014年04月24日 ページ情報: 英文 119 Pages
概要

当レポートでは、再発性の急性骨髄性白血病に関する臨床研究の最新動向について分析し、疾患・治療法の概要や、主な先進国・新興国における治験の状況、地域・フェーズ(相)・段階別の進行状況、有望なスポンサー、各企業・研究機関での研究の進行状況、有望な薬剤の比較といった情報を盛り込んで、概略以下の構成でお届けします。

目次

イントロダクション

  • 再発性の急性骨髄性白血病
  • 当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • アジア太平洋地域上位5ヶ国における治験件数
    • 欧州上位5ヶ国における治験件数
    • 北米の主要国における治験件数
    • 中東・アフリカの主要国における治験件数
    • 中南米の主要国における治験件数

G7諸国での治験件数:腫瘍全体に対する比率

G7諸国での治験件数:フェーズ(相)別

G7諸国での治験件数:進捗状況別

E7諸国での治験件数:腫瘍全体に対する比率

E7諸国での治験件数:フェーズ(相)別

E7諸国での治験件数:進捗状況別

フェーズ(相)別の治験件数

  • 進行中の治験:フェーズ別

進捗状況別の治験件数

治験の目標の達成状況

未完了の治験件数

一定期間に採用された被験者

スポンサーの種類別の治験件数

有望なスポンサー

  • 再発性の急性骨髄性白血病の治療薬の治験に参加している上位企業

有望な薬剤

治験の最新動向(全5件)

治験のプロファイル

  • 代表的企業の治験の概要
    • Novartis AG
    • Pfizer Inc.
    • Sanofi
    • C. H. Boehringer Sohn AG & Co. KG
    • Ambit Biosciences Corporation
    • F. Hoffmann-La Roche Ltd.
    • Chroma Therapeutics Ltd.
    • Celator Pharmaceuticals, Inc.
    • AROG Pharmaceuticals LLC
    • Amgen Inc.
  • 代表的な研究機関・病院の治験の概要
    • National Cancer Institute
    • Fred Hutchinson Cancer Research Center
    • The University of Texas M. D. Anderson Cancer Center
    • Children's Oncology Group
    • Washington University School of Medicine
    • Stanford University
    • Roswell Park Cancer Institute
    • University of California, San Francisco
    • Case Comprehensive Cancer Center

5つの代表的な治験のプロファイル

付録

図表一覧

目次
Product Code: GDHC2099CTIDB

GlobalData's clinical trial report, "Relapsed Acute Myeloid Leukemia Global Clinical Trials Review, H1, 2014" provides data on the Relapsed Acute Myeloid Leukemia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Relapsed Acute Myeloid Leukemia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Relapsed Acute Myeloid Leukemia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
  • Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  • Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

  • Understand the dynamics of a particular indication in a condensed manner
  • Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  • Obtain discontinued trial listing for trials across the globe
  • Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Relapsed Acute Myeloid Leukemia
    • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Relapsed Acute Myeloid Leukemia to Oncology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Relapsed Acute Myeloid Leukemia to Oncology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Unaccomplished Trials of Relapsed Acute Myeloid Leukemia
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials
  • Prominent Drugs
  • Latest Clinical Trials News on Relapsed Acute Myeloid Leukemia
    • Aug 28, 2013: Astex Pharmaceuticals Announces Topline Results of SGI-110 AML Phase 2 Study
    • Jun 25, 2013: FDA Issues Partial Clinical Hold On Cell Therapeutics's Tosedostat For Treatment Of Blood Cancer
    • Jun 13, 2013: Sunesis Pharma Announces Data And Safety Monitoring Board Recommends Continuation Of VALOR Trial With No Change To Study Conduct
    • Apr 01, 2013: Clavis Pharma Reports Negative Outcome Of Phase III CLAVELA Trial With Elacytarabine In Patients With Acute Myeloid Leukemia
    • Nov 28, 2012: Coronado Biosciences Initiates Phase I/II Trial Of CNDO-109 Activated Allogeneic Natural Killer Cells In Acute Myeloid Leukemia
  • Clinical Trial Profiles
    • Clinical Trial Overview of Top Companies
      • Novartis AG
      • Clinical Trial Overview of Novartis AG
      • Pfizer Inc.
      • Clinical Trial Overview of Pfizer Inc.
      • Sanofi
      • Clinical Trial Overview of Sanofi
      • C. H. Boehringer Sohn AG & Co. KG
      • Clinical Trial Overview of C. H. Boehringer Sohn AG & Co. KG
      • Ambit Biosciences Corporation
      • Clinical Trial Overview of Ambit Biosciences Corporation
      • F. Hoffmann-La Roche Ltd.
      • Clinical Trial Overview of F. Hoffmann-La Roche Ltd.
      • Chroma Therapeutics Ltd.
      • Clinical Trial Overview of Chroma Therapeutics Ltd.
      • Celator Pharmaceuticals, Inc.
      • Clinical Trial Overview of Celator Pharmaceuticals, Inc.
      • AROG Pharmaceuticals LLC
      • Clinical Trial Overview of AROG Pharmaceuticals LLC
      • Amgen Inc.
      • Clinical Trial Overview of Amgen Inc.
    • Clinical Trial Overview of Top Institutes / Government
      • National Cancer Institute
      • Clinical Trial Overview of National Cancer Institute
      • Fred Hutchinson Cancer Research Center
      • Clinical Trial Overview of Fred Hutchinson Cancer Research Center
      • The University of Texas M. D. Anderson Cancer Center
      • Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center
      • Children's Oncology Group
      • Clinical Trial Overview of Children's Oncology Group
      • Washington University School of Medicine
      • Clinical Trial Overview of Washington University School of Medicine
      • Stanford University
      • Clinical Trial Overview of Stanford University
      • Roswell Park Cancer Institute
      • Clinical Trial Overview of Roswell Park Cancer Institute
      • University of California, San Francisco
      • Clinical Trial Overview of University of California, San Francisco
      • Case Comprehensive Cancer Center
      • Clinical Trial Overview of Case Comprehensive Cancer Center
  • Five Key Clinical Profiles
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Relapsed Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Region, 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Europe, Top Five Countries, 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, North America, Top Countries, 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Central and South America, Top Countries, 2014*
  • Proportion of Relapsed Acute Myeloid Leukemia to Oncology Clinical Trials, G7 Countries (%), 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Relapsed Acute Myeloid Leukemia to Oncology Clinical Trials, E7 Countries (%), 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Phase, 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials In Progress by Phase 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics, Global, Withdrawn Clinical Trials, 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics, Global, Terminated Clinical Trials, 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Relapsed Acute Myeloid Leukemia Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by C. H. Boehringer Sohn AG & Co. KG, 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Ambit Biosciences Corporation, 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Chroma Therapeutics Ltd., 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Celator Pharmaceuticals, Inc., 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by AROG Pharmaceuticals LLC, 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Fred Hutchinson Cancer Research Center, 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Children's Oncology Group, 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Washington University School of Medicine, 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Stanford University, 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Roswell Park Cancer Institute, 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, San Francisco, 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Case Comprehensive Cancer Center, 2014*

List of Figures

  • Relapsed Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Region (%), 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, North America, Top Countries (%), 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014*
  • Proportion of Relapsed Acute Myeloid Leukemia to Oncology Clinical Trials, G7 Countries (%), 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Relapsed Acute Myeloid Leukemia to Oncology Clinical Trials, E7 Countries (%), 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Phase (%), 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials In Progress by Phase, 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Relapsed Acute Myeloid Leukemia Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • GlobalData Methodology
Back to Top